(CercleFinance.com) – Moderna announces that the UK MHRA has granted conditional authorization for its mRNA-1273.214 bivalent vaccine (Spikevax Bivalent Original/Omicron) as a booster dose to prevent Covid-19 in people aged 18 and over. more.
This decision is based on a Phase 2/3 trial, in which mRNA-1273.214 met all primary endpoints, including a superior neutralizing antibody response against Omicron compared to a booster dose of 50 μg mRNA-1273.
Moderna is working with local authorities to make the product available to the UK public. It has completed regulatory submissions in Australia, Canada and the EU and expects further clearance decisions in the coming weeks.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
